DR. KELLY ANN SMITH, MD
Osteopathic Medicine at Neff Rd, Bend, OR

5827538, Oct 27, 1998

Jan 17, 1996

8/571980

Edward L. Cussler - Edina MN
Scott M. Herbig - Bend OR
Kelly L. Smith - Bend OR
Paul van Eikeren - Bend OR

Pfizer Inc. - New York NY

A61K 924

424473

An osmotic device that, following the imbibement of water vapor, provides for the controlled release of a beneficial agent to an aqueous environment. The device comprises a hydrophilic formulation including a beneficial agent, and if needed, an osmagent, surrounded by a wall. The wall is formed at least in part of a semipermeable hydrophobic membrane having an average pore size between about 0. 1. mu. m and 30. mu. m. The pores are substantially filled with a gas phase. The hydrophobic membrane is permeable to water in the vapor phase and the hydrophobic membrane is impermeable to an aqueous medium at a pressure less than about 100 Pa. The beneficial agent is released, for example, by osmotic pumping or osmotic bursting upon imbibement of sufficient water vapor into the device core. These devices minimize incompatibilities between the beneficial agent and ions (such as hydrogen or hydroxyl) or other dissolved or suspended materials in the aqueous medium, since contact between the beneficial agent and the aqueous medium does not occur until after the beneficial agent is released. This results from the semipermeable membrane's selective permeability for water vapor.

2007008, Apr 19, 2007

Dec 14, 2006

11/610603

Leah Appel - Bend OR, US
Ronald Beyerinck - Bend OR, US
Mark Chidlaw - Bend OR, US
William Curatolo - Niantic CT, US
Dwayne Friesen - Bend OR, US
Kelly Smith - Bend OR, US
Avinash Thombre - East Lyme CT, US

A61K 9/24

424472000

A controlled release dosage form has a coated core with the core comprising a drug-containing composition and a water-swellable composition, each occupying separate regions within the core. The drug-containing composition comprises a low-solubility drug and a drug-entraining agent. The coating around the core is water-permeable, water-insoluble and has at least one delivery port therethrough. A variety of formulations having specific drug release profiles are disclosed.

2002001, Feb 7, 2002

Dec 20, 2000

09/745095

Leah Appel - Bend OR, US
Ronald Beyerinck - Bend OR, US
Mark Chidlaw - Bend OR, US
William Curatolo - Niantic CT, US
Dwayne Friesen - Bend OR, US
Kelly Smith - Bend OR, US
Avinash Thombre - East Lyme CT, US

A61K009/24

424/473000

A controlled release dosage form has a coated core with the core comprising a drug-containing composition and a water-swellable composition, each occupying separate regions within the core. The drug-containing composition comprises a low-solubility drug and a drug-entraining agent. The coating around the core is water-permeable, water-insoluble and has at least one delivery port therethrough. A variety of formulations having specific drug release profiles are disclosed.

4948506, Aug 14, 1990

Nov 14, 1988

7/272213

Harold K. Lonsdale - Bend OR
Walter C. Babcock - Bend OR
Dwayne T. Friensen - Bend OR
Kelly L. Smith - Bend OR
Bruce M. Johnson - Bend OR
Carl C. Wamser - West Linn OR

Bend Research, Inc. - Bend OR

B01D 1300

210490

Interfacially-polymerized ultrathin films containing physicochemically functional groups are disclosed, both with and without supports. Various applications are disclsoed, including membrane electrodes, selective membranes and sorbents, biocompatible materials, targeted drug delivery, and narrow band optical absorbers.

5888930, Mar 30, 1999

Mar 13, 1997

8/828825

Kelly L. Smith - Bend OR
Matthew F. Holmes - Bend OR
James W. Brooke - Sisters OR

Bend Research, Inc. - Bend OR

A01N 2534, A61K 952

504116

A durable and sprayable controlled release bead of active ingredient in the pores of a polymeric micro-porous bead having an anisotropic pore structure of large pores in the interior and small pores at the surface, the gradation of pore sizes between the interior and the surface being continuous.

5603953, Feb 18, 1997

May 23, 1995

8/424511

Scott M. Herbig - Bend OR
Kelly L. Smith - Bend OR
Paul Van Eikeren - Carlisle MA
James B. West - Bend OR

Pfizer Inc. - New York NY

A61K 930, A61K 932, A61K 936, A61K 922

424473

Supported liquid membrane delivery devices that release a beneficial agent to an aqueous environment following exposure to an environmental trigger. A microporous hydrophobic support membrane at least partially surrounds a beneficial agent- containing hydrophilic formulation. A hydrophobic liquid is held within the microporous support membrane by capillarity and the hydrophobic liquid is substantially permeable to the aqueous environment and the beneficial agent-containing hydrophilic formulation. The entrained hydrophobic liquid becomes substantially permeable to the aqueous environment upon exposure to an environmental trigger such as an enzyme, and the beneficial agent is subsequently released.

2011018, Jul 28, 2011

Dec 27, 2010

12/979278

Leah E. Appel - Bend OR, US
Ronald A. Beyerinck - Bend OR, US
Mark B. Chidlaw - Bend OR, US
William J. Curatolo - Niantic CT, US
Dwayne T. Friesen - Bend OR, US
Kelly L. Smith - Bend OR, US
Avinash G. Thombre - East Lyme CT, US

A61K 9/00, A61K 31/135, A61K 31/404, A61P 25/24, A61P 29/00, A61K 31/403, A61K 31/496, A61K 31/519, A61P 15/10

424400, 514647, 514414, 514411, 51425404, 51425216

A controlled release dosage form has a coated core with the core comprising a drug-containing composition and a water-swellable composition, each occupying separate regions within the core. The drug-containing composition comprises a low-solubility drug and a drug-entraining agent. The coating around the core is water-permeable, water-insoluble and has at least one delivery port therethrough. A variety of formulations having specific drug release profiles are disclosed.

5750126, May 12, 1998

Jan 11, 1996

8/584986

Kelly L. Smith - Bend OR
Scott H. Herbig - Bend OR

Bend Research, Inc. - Bend OR

A01N 2528

424405

There is disclosed a pesticidal composition comprising a pH-sensitive non-lignin-based polymer encapsulating both the active agent and a lignin-based UV screening agent.

5698220, Dec 16, 1997

Jun 5, 1995

8/462473

John R. Cardinal - Old Lyme CT
Scott M. Herbig - Bend OR
Richard W. Korsmeyer - East Lyme CT
Jeelin Lo - Old Lyme CT
Kelly L. Smith - Bend OR
Avinash G. Thombre - Gales Ferry CT

Pfizer Inc. - New York NY

A61K 962, A61K 936

424451

A device for controlled release of an active substance through one or more asymmetric membranes by diffusion and/or osmotic pumping.

4769027, Sep 6, 1988

Feb 24, 1987

7/016966

Richard W. Baker - Mountain View CA
Kelly L. Smith - Bend OR
James W. Brooke - Sisters OR

Burroughs Wellcome Co. - Research Triangle Park NC

A61M 3100

424493

Prills of pharmaceutically acceptable material are coated first with a water-permeable polymeric matrix containing a water-soluble pharmaceutically beneficial agent and then overcoated with a water-permeable film containing dispersed therein a water-soluble, particulate pore-forming material.